Send to

Choose Destination
Calcif Tissue Int. 1994 Jan;54(1):26-9.

Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover.

Author information

Division of Gerontology, Charles A. Dana Research Institute, Boston, Massachusetts.


Urinary excretion of cross-linked N-telopeptide of type I collagen (NTX) has been reported to be a specific indicator of bone resorption. We studied the utility of a new immunoassay for NTX as an indicator of changes in bone resorption caused by treatment with pamidronate (APD) followed by T3. Twenty-two male subjects received either placebo (Group 1) or APD on study days 1-2 (Group 2). One week later all subjects received T3 100 micrograms/day (days 8-15). Urinary NTX, pyridinoline (PYD), hydroxyproline (HYP), and creatinine (cr) were measured on 2-hour fasting urine samples at baseline (day 1), after APD/placebo (day 8), after T3 (day 16), and at days 30 and 58. NTX/cr excretion fell 85% after treatment with APD (P < 0.001 versus baseline), but not after placebo. The fall in mean urinary NTX after receiving APD was greater than the fall in PYD (25%) or HYP (31%) (P < 0.001 NTX versus PYD and HYP). After treatment with APD, NTX excretion remained suppressed below baseline until day 58, whereas PYD and HYP excretion returned to baseline by study day 16. Persistence of APD's effect on bone until day 58 was suggested by the fact that serum calcium and parathyroid hormone levels had not returned to baseline by day 58. On day 16, after all subjects were treated with T3, urinary NTX/cr rose significantly (P < 0.01) in Group 1 (-bisphosphonate) but not in Group 2 (+bisphosphonate).(ABSTRACT TRUNCATED AT 250 WORDS).

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center